LEO Pharma works according to detailed clinical trial disclosure policies announced in October 2013. LEO Pharma was the second pharmaceutical company globally to declare its commitment to increased data transparency and, as a patient-focused company, considers public registration of clinical trials to be a scientific and ethical responsibility, facilitating informed healthcare decisions and promoting patient safety by ensuring all available evidence is accessible without publication bias or selective reporting.
LEO Pharma currently meets, and in some cases exceeds, existing requirements from authorities regarding the disclosure of clinical trial results. LEO Pharma has an independent global Patient and Scientific Review Board consisting of three external researchers and two representatives from patient associations, to review any applications for access to patient level data.
More information on our global clinical trial disclosure policy can be viewed at our global site by clicking here.
Information on LEO Pharma clinical trials is available on www.ClinicalTrials.gov, a public website provided by the U.S. National Library of Medicine (NLM).